We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Enhertu Shows Promise in Late Stage Study for HER2-Positive Metastatic Breast Cancer
Enhertu Shows Promise in Late Stage Study for HER2-Positive Metastatic Breast Cancer
AstraZeneca (AZ) and Daiichi Sankyo have announced that an interim analysis from a phase 3 trial showed that their antibody-drug conjugate Enhertu (trastuzumab deruxtecan) posted positive progression-free survival relative to trastuzumab emtansine (T-DM1).